- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease.
Hepion Pharmaceuticals (HEPA) Reports Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ALTITUDE-NASH Liver Function Trial of Rencofilstat streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 373,700 shares, a decline of 11.4% from the September 30th total of 421,900 shares. Based on an average daily trading volume, of 30,300 shares, the short-interest […]
Hepion Pharmaceuticals (HEPA) Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.